A Phase 1 interventional study of carboplatin and docetaxel in Solid Cancers, sponsored by Genentech, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-10.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with HER2-positive metastatic or locally advanced inoperable cancer.
The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. The QTcF interval is the QT interval as calculated using Fridericia's correction; the QTcB interval is the QT interval as calculated using Bazett's correction.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: carboplatin · Drug: docetaxel · Drug: trastuzumab
Intravenous repeating dose
Intravenous repeating dose
Intravenous repeating dose
Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Trastuzumab steady state was defined as the average of the 2 ECG measurements collected on Cycle 1 Day 8 (C1D8) and Cycle 2 Day 1 (C2D1) after the trastuzumab infusion.
Time frame: Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Maximum Observed Plasma Concentration (Cmax) of Carboplatin
Time frame: 0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Area Under the Curve From Time Zero to 6 Hours Post Infusion (AUC0-6hr) of Carboplatin
AUC0-6hr = Area under the plasma concentration versus time curve from 0 to 6 hours post-infusion.
Time frame: 0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Dose-Normalized Cmax (Cmax/D) of Carboplatin
Dose normalized Cmax is the maximum observed concentration of carboplatin in plasma normalized for different dose levels.
Time frame: 0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Geometric Mean Ratio of Cmax/D of Carboplatin
The geometric mean ratio of Cmax of carboplatin was defined as the Cmax/D of carboplatin on Cycle 1 Day 1 (in the absence of trastuzumab) divided by Cmax/D of carboplatin on Cycle 2 Day 1 (in the presence of trastuzumab).
Time frame: 0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Dose-Normalized AUC0-6hr (AUC0-6hr/D) of Carboplatin
AUC0-6hr/D = Area under the plasma concentration versus time curve from 0 to 6 hours post-infusion, normalized by carboplatin dose level.
Time frame: 0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Geometric Mean Ratio of AUC0-6hr/D of Carboplatin
The geometric mean ratio of AUC0-6hr/D of carboplatin was defined as the AUC0-6hr/D of carboplatin on Cycle 1 Day 1 (in the absence of trastuzumab) divided by AUC0-6hr/D of carboplatin on Cycle 2 Day 1 (in the presence of trastuzumab).
Time frame: 0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Plasma Decay Half-Life (t1/2) of Carboplatin
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Maximum Observed Serum Concentration (Cmax) of Trastuzumab
Time frame: 30 (±15) minutes after the end of the infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1
Minimum Observed Serum Trough Concentration (Cmin) of Trastuzumab
Time frame: 15 (±15) minutes prior to the start of the trastuzumab infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1
Change From Baseline in Corrected QT Interval Using Bazett's Correction (QTcB) at Trastuzumab Steady State
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Bazette's formula (QTcB = QT divided by square root of RR). Trastuzumab steady state was defined as the average of the 2 ECG measurements collected on Cycle 1 Day 8 and Cycle 2 Day 1 after the trastuzumab infusion.
Time frame: Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Baseline-adjusted QTcF, QTcB, PR Interval, and QRS Duration
For each postbaseline timepoint, a participant's corresponding baseline measure was subtracted from his or her average of the triplicate ECG measure to create a "baseline-adjusted" corresponding ECG measure for each participant at each postbaseline timepoint.
Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Baseline-adjusted Heart Rate
For each postbaseline timepoint, a participant's corresponding baseline heart rate was subtracted from his or her average of the triplicate heart rate to create a "baseline-adjusted" corresponding heart rate for each participant at each postbaseline timepoint.
Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Number of Participants Within Each Absolute QTc Interval Category
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc less than or equal to (\<=) 450 msec, greater than (\>) 450 to \<=470 msec, \>470 to \<= 500 msec, or \>500 msec were reported.
Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Number of Participants With Increase From Baseline in QTc Interval
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of =\>30msec, 30 to \<60 msec (borderline) and \>=60 msec (prolonged) were summarized.
Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Number of Participants With New Abnormal U Waves on ECG
The incidence of abnormal U-wave changes from baseline was determined based on centrally read ECG tracings comparing each of the three triplicate readings from the post baseline ECG time points to the baseline ECG reading. At each time point, if at least one of the three triplicate readings was abnormal, the participant was counted as abnormal for that ECG timepoint as follows: a large U wave, inverted U wave, or T-U fusion compared with baseline was considered an abnormal significant change from baseline.
Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Number of Participants With New Abnormal T Waves on ECG
The incidence of abnormal T-wave changes from baseline was determined based on centrally read ECG tracings comparing each of the three triplicate readings from the post baseline ECG time points to the baseline ECG reading. At each time point, if at least one of the three triplicate readings was abnormal, the participant was counted as abnormal for that ECG timepoint as follows: an inverted T, flat T, or biphasic T compared with baseline was considered an abnormal significant change from baseline. Additionally, nonspecific T-wave changes from baseline were considered as abnormal nonsignificant changes from baseline. T-wave changes from baseline due to ventricular conduction or left ventricular hypertrophy strain were considered not evaluable.
Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Number of Participants With Abnormal Changes in PR Interval
Criteria for abnormal changes in PR interval were defined as: =\>25 percentage (%) change from baseline, an absolute value \>200 msec, or \>=25% change from baseline and an absolute value \>200 msec.
Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Number of Participants With Abnormal Changes in QRS Interval
Criteria for abnormal changes in QRS interval were defined as: \>=25% change from baseline, an absolute value \>110 msec, or \>=25% change from baseline and an absolute value \>110 msec.
Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Population Pharmacokinetics of Trastuzumab
As per planned analysis, separate population pharmacokinetic analysis results are not available for the current study as this analysis is based on pooled data from multiple studies.
Time frame: 15 (±15) minutes prior to the start of the trastuzumab infusion, and 30 (±15) minutes after the end of the infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1
| Milestone | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Started | 59 |
| Completed | 43 |
| Not completed | 16 |
| Withdrew: Death | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Disease progression | 8 |
| Withdrew: Non-compliance | 1 |
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Trastuzumab steady state was defined as the average of the 2 ECG measurements collected on Cycle 1 Day 8 (C1D8) and Cycle 2 Day 1 (C2D1) after the trastuzumab infusion.
| milliseconds (msec) | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State | -8.4 (-11.1 to -5.7) |
| Microgram per milliliter (mcg/mL) | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Cycle 1 Day 1 (in absence of trastuzumab) | 51 ± 15.13 |
| Cycle 2 Day 1 (in presence of trastuzumab) | 52 ± 16.58 |
AUC0-6hr = Area under the plasma concentration versus time curve from 0 to 6 hours post-infusion.
| Hour*microgram/milliliter (hr*mcg/mL) | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Cycle 1 Day 1 (in absence of trastuzumab) | 115 ± 28.63 |
| Cycle 2 Day 1 (in presence of trastuzumab) | 123 ± 34.99 |
Dose normalized Cmax is the maximum observed concentration of carboplatin in plasma normalized for different dose levels.
| (mcg/mL)/(min*mg/mL) | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Cycle 1 Day 1 (in absence of trastuzumab) | 9 ± 2.52 |
| Cycle 2 Day 1 (in presence of trastuzumab) | 9 ± 2.76 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Bazette's formula (QTcB = QT divided by square root of RR). Trastuzumab steady state was defined as the average of the 2 ECG measurements collected on Cycle 1 Day 8 and Cycle 2 Day 1 after the trastuzumab infusion.
| msec | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Change From Baseline in Corrected QT Interval Using Bazett's Correction (QTcB) at Trastuzumab Steady State | -5.9 (-9.2 to -2.6) |
For each postbaseline timepoint, a participant's corresponding baseline measure was subtracted from his or her average of the triplicate ECG measure to create a "baseline-adjusted" corresponding ECG measure for each participant at each postbaseline timepoint.
| msec | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| QTcF: Cycle 1 Day 2 (30 minutes postdose) (n=49) | 3.5 ± 11.8 |
| QTcF: Cycle 1 Day 8 (15 minutes predose) (n=50) | -9.3 ± 12.1 |
| QTcF: Cycle 1 Day 8 (30 minutes postdose) (n=50) | -4.3 ± 12.0 |
| QTcF: Cycle 2 Day 1 (15 minutes predose) (n=48) | -15.6 ± 13.3 |
| QTcF: Cycle 2 Day 1 (30 minutes postdose) (n=48) | -13.4 ± 14.6 |
| QTcB: Cycle 1 Day 2 (30 minutes postdose) (n=49) | 3.9 ± 9.7 |
| QTcB: Cycle 1 Day 8 (15 minutes predose) (n=50) | -0.8 ± 14.5 |
| QTcB: Cycle 1 Day 8 (30 minutes postdose) (n=50) | 1.4 ± 14.6 |
| QTcB: Cycle 2 Day 1 (15 minutes predose) (n=48) | -13.2 ± 16.6 |
| QTcB: Cycle 2 Day 1 (30 minutes postdose) (n=48) | -14.2 ± 18.6 |
| PR: Cycle 1 Day 2 (30 minutes postdose) (n=49) | -0.1 ± 9.4 |
| PR: Cycle 1 Day 8 (15 minutes predose) (n=50) | 1.4 ± 14.6 |
| PR: Cycle 1 Day 8 (30 minutes postdose) (n=50) | 4.2 ± 11.8 |
| PR: Cycle 2 Day 1 (15 minutes predose) (n=48) | 9.7 ± 13.1 |
| PR: Cycle 2 Day 1 (30 minutes postdose) (n=48) | 13.7 ± 16.1 |
| QRS: Cycle 1 Day 2 (30 minutes postdose) (n=49) | -0.1 ± 4.0 |
| QRS: Cycle 1 Day 8 (15 minutes predose) (n=50) | -1.8 ± 5.5 |
| QRS: Cycle 1 Day 8 (30 minutes postdose) (n=50) | -1.8 ± 5.8 |
| QRS: Cycle 2 Day 1 (15 minutes predose) (n=48) | -0.5 ± 5.0 |
| QRS: Cycle 2 Day 1 (30 minutes postdose) (n=48) | -0.3 ± 6.0 |
For each postbaseline timepoint, a participant's corresponding baseline heart rate was subtracted from his or her average of the triplicate heart rate to create a "baseline-adjusted" corresponding heart rate for each participant at each postbaseline timepoint.
| beats per minute (bpm) | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Cycle 1 Day 2 (30 minutes postdose) (n=49) | 0.5 ± 9.9 |
| Cycle 1 Day 8 (15 minutes predose) (n=50) | 9.6 ± 14.9 |
| Cycle 1 Day 8 (30 minutes postdose) (n=50) | 6.2 ± 13.7 |
| Cycle 2 Day 1 (15 minutes predose) (n=48) | 3.1 ± 12.7 |
| Cycle 2 Day 1 (30 minutes postdose) (n=48) | -0.7 ± 12.1 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc less than or equal to (\<=) 450 msec, greater than (\>) 450 to \<=470 msec, \>470 to \<= 500 msec, or \>500 msec were reported.
| participants | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| QTcF<=450 msec: C1D2 30 min postdose (n=49) | 44 |
| QTcF >450 to <=470 msec:C1D2 30min postdose (n=49) | 4 |
| QTcF >470 to <=500 msec: C1D2 30min postdose(n=49) | 1 |
| QTcF >500 msec: C1D2 30 min postdose (n=49) | 0 |
| QTcF<=450 msec: C1D8 15 min predose (n=50) | 49 |
| QTcF >450 to <=470 msec: C1D8 15 min predose(n=50) | 1 |
| QTcF >470 to <=500 msec: C1D8 15 min predose(n=50) | 0 |
| QTcF >500 msec: C1D8 15 min predose (n=50) | 0 |
| QTcF<=450 msec: C1D8 30 min postdose (n=50) | 48 |
| QTcF >450 to <=470 msec: C1D8 30min postdose(n=50) | 2 |
| QTcF >470 to <=500 msec: C1D8 30min postdose(n=50) | 0 |
| QTcF >500 msec: C1D8 30 min postdose (n=50) | 0 |
| QTcF<=450 msec: C2D1 15 min predose (n=48) | 48 |
| QTcF >450 to <=470 msec: C2D1 15 min predose(n=48) | 0 |
| QTcF >470 to <=500 msec: C2D1 15 min predose(n=48) | 0 |
| QTcF >500 msec: C2D1 15 min predose (n=48) | 0 |
| QTcF<=450 msec: C2D1 30 min postdose (n=48) | 48 |
| QTcF >450 to <=470 msec: C2D1 30min postdose(n=48) | 0 |
| QTcF >470 to <=500 msec: C2D1 30min postdose(n=48) | 0 |
| QTcF >500 msec: C2D1 30 min postdose (n=48) | 0 |
| QTcB<=450 msec: C1D2 30 min postdose (n=49) | 36 |
| QTcB >450 to <=470 msec:C1D2 30min postdose (n=49) | 10 |
| QTcB >470 to <=500 msec: C1D2 30min postdose(n=49) | 2 |
| QTcB >500 msec: C1D2 30 min postdose (n=49) | 1 |
| QTcB<=450 msec: C1D8 15 min predose (n=50) | 41 |
| QTcB >450 to <=470 msec: C1D8 15 min predose(n=50) | 7 |
| QTcB >470 to <=500 msec: C1D8 15 min predose(n=50) | 2 |
| QTcB >500 msec: C1D8 15 min predose (n=50) | 0 |
| QTcB<=450 msec: C1D8 30 min postdose (n=50) | 39 |
| QTcB >450 to <=470 msec: C1D8 30min postdose(n=50) | 9 |
| QTcB >470 to <=500 msec: C1D8 30min postdose(n=50) | 2 |
| QTcB >500 msec: C1D8 30 min postdose (n=50) | 0 |
| QTcB<=450 msec: C2D1 15 min predose (n=48) | 43 |
| QTcB >450 to <=470 msec: C2D1 15 min predose(n=48) | 4 |
| QTcB >470 to <=500 msec: C2D1 15 min predose(n=48) | 1 |
| QTcB >500 msec: C2D1 15 min predose (n=48) | 0 |
| QTcB<=450 msec: C2D1 30 min postdose (n=48) | 43 |
| QTcB >450 to <=470 msec: C2D1 30min postdose(n=48) | 5 |
| QTcB >470 to <=500 msec: C2D1 30min postdose(n=48) | 0 |
| QTcB >500 msec: C2D1 30 min postdose (n=48) | 0 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of =\>30msec, 30 to \<60 msec (borderline) and \>=60 msec (prolonged) were summarized.
| participants | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| QTcF<=30 msec: C1D2 30 min postdose (n=49) | 49 |
| QTcF >30 to <=60 msec:C1D2 30 min postdose (n=49) | 0 |
| QTcF >60 msec: C1D2 30 min postdose (n=49) | 0 |
| QTcF<=30 msec: C1D8 15 min predose (n=50) | 50 |
| QTcF >30 to <=60 msec: C1D8 15 min predose (n=50) | 0 |
| QTcF >60 msec: C1D8 15 min predose (n=50) | 0 |
| QTcF<=30 msec: C1D8 30 min postdose (n=50) | 50 |
| QTcF >30 to <=60 msec: C1D8 30 min postdose (n=50) | 0 |
| QTcF >60 msec: C1D8 30 min postdose (n=50) | 0 |
| QTcF<=30 msec: C2D1 15 min predose (n=48) | 48 |
| QTcF >30 to <=60 msec: C2D1 15 min predose (n=48) | 0 |
| QTcF >60 msec: C2D1 15 min predose (n=48) | 0 |
| QTcF<=30 msec: C2D1 30 min postdose (n=48) | 48 |
| QTcF >30 to <=60 msec: C2D1 30min postdose (n=48) | 0 |
| QTcF >60 msec: C2D1 30 min postdose (n=48) | 0 |
| QTcB<=30 msec: C1D2 30 min postdose (n=49) | 49 |
| QTcB >30 to <=60 msec:C1D2 30 min postdose (n=49) | 0 |
| QTcB >60 msec: C1D2 30 min postdose (n=49) | 0 |
| QTcB<=30 msec: C1D8 15 min predose (n=50) | 50 |
| QTcB >30 to <=60 msec: C1D8 15 min predose (n=50) | 0 |
| QTcB >60 msec: C1D8 15 min predose (n=50) | 0 |
| QTcB<=30 msec: C1D8 30 min postdose (n=50) | 49 |
| QTcB >30 to <=60 msec: C1D8 30 min postdose (n=50) | 1 |
| QTcB >60 msec: C1D8 30 min postdose (n=50) | 0 |
| QTcB<=30 msec: C2D1 15 min predose (n=48) | 48 |
| QTcB >30 to <=60 msec: C2D1 15 min predose (n=48) | 0 |
| QTcB >60 msec: C2D1 15 min predose (n=48) | 0 |
| QTcB<=30 msec: C2D1 30 min postdose (n=48) | 48 |
| QTcB >30 to <=60 msec: C2D1 30min postdose (n=48) | 0 |
| QTcB >60 msec: C2D1 30 min postdose (n=48) | 0 |
The incidence of abnormal U-wave changes from baseline was determined based on centrally read ECG tracings comparing each of the three triplicate readings from the post baseline ECG time points to the baseline ECG reading. At each time point, if at least one of the three triplicate readings was abnormal, the participant was counted as abnormal for that ECG timepoint as follows: a large U wave, inverted U wave, or T-U fusion compared with baseline was considered an abnormal significant change from baseline.
| participants | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| C1D2 30 min postdose (n=49) | 0 |
| C1D8 15 min predose (n=50) | 0 |
| C1D8 30 min postdose (n=50) | 0 |
| C2D1 15 min predose (n=48) | 0 |
| C2D1 30 min postdose (n=48) | 0 |
The incidence of abnormal T-wave changes from baseline was determined based on centrally read ECG tracings comparing each of the three triplicate readings from the post baseline ECG time points to the baseline ECG reading. At each time point, if at least one of the three triplicate readings was abnormal, the participant was counted as abnormal for that ECG timepoint as follows: an inverted T, flat T, or biphasic T compared with baseline was considered an abnormal significant change from baseline. Additionally, nonspecific T-wave changes from baseline were considered as abnormal nonsignificant changes from baseline. T-wave changes from baseline due to ventricular conduction or left ventricular hypertrophy strain were considered not evaluable.
| participants | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| C1D2 30 min postdose (n=49) | 0 |
| C1D8 15 min predose (n=50) | 0 |
| C1D8 30 min postdose (n=50) | 0 |
| C2D1 15 min predose (n=48) | 0 |
| C2D1 30 min postdose (n=48) | 0 |
Criteria for abnormal changes in PR interval were defined as: =\>25 percentage (%) change from baseline, an absolute value \>200 msec, or \>=25% change from baseline and an absolute value \>200 msec.
| participants | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| >=25% change: C1D2 30 min postdose (n=49) | 0 |
| Absolute value >200msec: C1D2 30min postdose(n=49) | 2 |
| >=25%change and >200msec:C1D2 30min postdose(n=49) | 0 |
| >=25% change: C1D8 15 min predose (n=50) | 1 |
| Absolute value >200msec: C1D8 15 min predose(n=50) | 1 |
| >=25%change and >200msec: C1D8 15min predose(n=50) | 1 |
| >=25% change: C1D8 30 min postdose (n=50) | 0 |
| Absolute value >200msec: C1D8 30min postdose(n=50) | 1 |
| >=25%change and >200msec:C1D8 30min postdose(n=50) | 0 |
| >=25% change: C2D1 15 min predose (n=48) | 2 |
| Absolute value >200msec: C2D1 15 min predose(n=48) | 4 |
| >=25%change and >200msec: C2D1 15min predose(n=48) | 1 |
| >=25% change: C2D1 30 min postdose (n=48) | 2 |
| Absolute value >200msec: C2D1 30min postdose(n=48) | 4 |
| >=25%change and >200msec:C2D1 30min postdose(n=48) | 1 |
Criteria for abnormal changes in QRS interval were defined as: \>=25% change from baseline, an absolute value \>110 msec, or \>=25% change from baseline and an absolute value \>110 msec.
| participants | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| >=25% change: C1D2 30 min postdose (n=49) | 0 |
| Absolute value >110msec: C1D2 30min postdose(n=49) | 4 |
| >=25%change and >110msec:C1D2 30min postdose(n=49) | 0 |
| >=25% change: C1D8 15 min predose (n=50) | 0 |
| Absolute value >110msec: C1D8 15 min predose(n=50) | 4 |
| >=25%change and >110msec: C1D8 15min predose(n=50) | 0 |
| >=25% change: C1D8 30 min postdose (n=50) | 0 |
| Absolute value >110msec: C1D8 30min postdose(n=50) | 4 |
| >=25%change and >110msec:C1D8 30min postdose(n=50 | 0 |
| >=25% change: C2D1 15 min predose (n=48) | 0 |
| Absolute value >110msec: C2D1 15 min predose(n=48) | 4 |
| >=25%change and >110msec: C2D1 15min predose(n=48) | 0 |
| >=25% change: C2D1 30 min postdose (n=48) | 0 |
| Absolute value >110msec: C2D1 30min postdose(n=48) | 4 |
| >=25%change and >110msec:C2D1 30min postdose(n=48) | 0 |
As per planned analysis, separate population pharmacokinetic analysis results are not available for the current study as this analysis is based on pooled data from multiple studies.
Results for this outcome have not been posted.
The geometric mean ratio of Cmax of carboplatin was defined as the Cmax/D of carboplatin on Cycle 1 Day 1 (in the absence of trastuzumab) divided by Cmax/D of carboplatin on Cycle 2 Day 1 (in the presence of trastuzumab).
| ratio | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Geometric Mean Ratio of Cmax/D of Carboplatin | 1.02 (0.90 to 1.15) |
AUC0-6hr/D = Area under the plasma concentration versus time curve from 0 to 6 hours post-infusion, normalized by carboplatin dose level.
| (hr*mcg/mL)/(min*mg/mL) | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Cycle 1 Day 1 (in absence of trastuzumab) | 19 ± 4.77 |
| Cycle 2 Day 1 (in presence of trastuzumab) | 21 ± 5.83 |
The geometric mean ratio of AUC0-6hr/D of carboplatin was defined as the AUC0-6hr/D of carboplatin on Cycle 1 Day 1 (in the absence of trastuzumab) divided by AUC0-6hr/D of carboplatin on Cycle 2 Day 1 (in the presence of trastuzumab).
| ratio | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Geometric Mean Ratio of AUC0-6hr/D of Carboplatin | 1.07 (0.96 to 1.18) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Cycle 1 Day 1 (in absence of trastuzumab) (n=44) | 2 ± 0.94 |
| Cycle 2 Day 1 (in presence of trastuzumab) (n=43) | 2 ± 1.12 |
| mcg/mL | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Cycle 1 Day 2 (n=57) | 146.3 (137.3 to 155.9) |
| Cycle 1 Day 8 (n=51) | 187.1 (173.1 to 202.3) |
| Cycle 2 Day 1 (n=48) | 179.1 (166.8 to 192.4) |
| Cycle 3 Day 1 (n=42) | 181.5 (169.5 to 194.4) |
| mcg/mL | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Cycle 1 Day 2 (n=57) | 0.178 (0.1 to 0.2) |
| Cycle 1 Day 8 (n=51) | 38.8 (30.7 to 49.2) |
| Cycle 2 Day 1 (n=48) | 38.7 (32.9 to 45.5) |
| Cycle 3 Day 1 (n=42) | 29.7 (24.5 to 36.1) |
Collected over Baseline up to study completion/early termination (28 to 42 days after the last administration of study treatment) (maximum treatment duration = 163 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab + Docetaxel + Carboplatin | — | 26/58 (44.8%) | 56/58 (96.6%) |
| Event | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 5/58 |
| Small intestinal obstructionGastrointestinal disorders | 3/58 |
| PneumoniaInfections and infestations | 3/58 |
| ColitisGastrointestinal disorders | 2/58 |
| DehydrationMetabolism and nutrition disorders | 2/58 |
| ConstipationGastrointestinal disorders | 1/58 |
| DiarrhoeaGastrointestinal disorders | 1/58 |
| Diverticular perforationGastrointestinal disorders | 1/58 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/58 |
| HaematemesisGastrointestinal disorders | 1/58 |
| Event | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Neutrophil count decreasedInvestigations | 37/58 |
| NauseaGastrointestinal disorders | 34/58 |
| Haemoglobin decreasedInvestigations | 33/58 |
| FatigueGeneral disorders | 31/58 |
| DiarrhoeaGastrointestinal disorders | 30/58 |
| Platelet count decreasedInvestigations | 23/58 |
| VomitingGastrointestinal disorders | 22/58 |
| AlopeciaSkin and subcutaneous tissue disorders | 18/58 |
| Decreased appetiteMetabolism and nutrition disorders | 17/58 |
| White blood cell count decreasedInvestigations | 16/58 |
All enrolled participants
| Age, Continuous(years) | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Mean | 59.0 ± 12.1 |
| Sex: Female, Male(Participants) | Trastuzumab + Docetaxel + Carboplatin |
|---|---|
| Female | 33 |
| Male | 26 |
The record gives a start of Jul 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboplatin · Docetaxel · Trastuzumab